The parametric g-formula to estimate the effect of highly active antiretroviral therapy on incident AIDS or death

Statistics in Medicine

Volumn 31, Issue 18, 2012, Pages 2000-2009

  Westreich, Daniel ^a   Cole, Stephen R ^b   Young, Jessica G ^c   Palella, Frank ^e   Tien, Phyllis C ^f,g   Kingsley, Lawrence ^h   Gange, Stephen J ⁱ   Hernán, Miguel A ^c,d  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b IL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^h UNIVERSITY OF PITTSBURGH   (United States)

ⁱ JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Cohort study; Confounding; G formula; HIV AIDS; Monte Carlo methods

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALGORITHM; ARTICLE; CALCULATION; CD4 LYMPHOCYTE COUNT; DEATH; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; INFECTION RISK; INTERMETHOD COMPARISON; MATHEMATICAL MODEL; PARAMETRIC G FORMULA; PROBABILITY; RISK FACTOR; SENSITIVITY ANALYSIS; SIMULATION; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DATA INTERPRETATION, STATISTICAL; FEMALE; HIV; HIV INFECTIONS; HUMANS; MALE; MODELS, STATISTICAL; PROSPECTIVE STUDIES; VIRAL LOAD;

EID: 84864000886     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.5316     Document Type: Article

References (35)

1. Robins JM.A new approach to causal inference in mortality studies with sustained exposure periods-application to control of the healthy worker survivor effect. Mathe Model 1986 7:1393-1512.
2. Robins JM.1998. Structural nested failure time models, In Encyclopedia of Biostatistics, Armitage P, Colton T (eds), John Wiley & Sons, Chichester, UK; 4372-4389.
3. Robins JM, Hernán MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000 11:550-560.
4. Hernán MA, Hernandez-Diaz S, Robins JM.A structural approach to selection bias. Epidemiology 2004 15(5): 615-625.
5. Cole SR, Platt RW, Schisterman EF, Chu H, Westreich D, Richardson D, Poole C. Illustrating bias due to conditioning on a collider. International Journal of Epidemiology 2010 39(2): 417-420.
6. Bodnar LM, Davidian M, Siega-Riz AM, Tsiatis AA. Marginal structural models for analyzing causal effects of time-dependent treatments: an application in perinatal epidemiology. American Journal of Epidemiology 2004 159(10): 926-934.
7. Sterne JA, Hernán MA, Ledergerber B, Tilling K, Weber R, Sendi P, Rickenbach M, Robins JM, Egger M. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet 2005 366(9483): 378-384.
8. Cole SR, Hernán MA, Anastos K, Jamieson BD, Robins JM. Determining the effect of highly active antiretroviral therapy on changes in human immunodeficiency virus type 1 RNA viral load using a marginal structural left-censored mean model. American Journal of Epidemiology 2007 166(2): 219-227.
9. Petersen ML, van der Laan MJ, Napravnik S, Eron JJ, Moore RD, Deeks SG. Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification. Aids 2008 22(16): 2097-2106.
10. López-Gatell H, Cole SR, Margolick JB, Witt MD, Martinson J, Phair JP, Jacobson LP. Effect of tuberculosis on the survival of HIV-infected men in a country with low tuberculosis incidence. Aids 2008 22(14): 1869-1873.
11. Almirall D, Ten Have T, Murphy SA. Structural nested mean models for assessing time-varying effect moderation. Biometrics 2010 66:131-139.
12. Robins J. The control of confounding by intermediate variables. Statistics in Medicine 1989 8(6): 679-701.
13. Robins J.A graphical approach to the identification and estimation of causal parameters in mortality studies with sustained exposure periods. Journal of Chronic Diseases 1987 40 Suppl 2:139S-161S.
14. Robins J, Hernán M, Siebert U.2004. Effects of multiple interventions, InGlobal and Regional Burden of Diseases Attributable to Selected Major Risk Factors, Vol. 2, Ezzati M, Lopez A, Rodgers A, Murray C (eds), World Health Organization, Geneva.
15. van der Wal WM, Prins M, Lumbreras B, Geskus RB.A simple g-computation algorithm to quantify the causal effect of a secondary illness on the progression of a chronic disease. Statistics in Medicine 2009 28(18): 2325-2337.
16. Snowden JM, Rose S, Mortimer KM. Implementation of g-computation on a simulated data set: demonstration of a causal inference technique. American Journal of Epidemiology 2011 173(7): 731-738.
17. Taubman SL, Robins JM, Mittleman MA, Hernan MA. Intervening on risk factors for coronary heart disease: an application of the parametric g-formula. International Journal of Epidemiology 2009 38(6): 1599-1611.
18. Young J, Cain L, Robins J, O'Reilly E, Hernán M. Comparative effectiveness of dynamic treatment regimes: an application of the parametric g-formula. Statistics in Biosciences 2011 3:119-143.
19. Cole SR, Hernán MA, Robins JM, Anastos K, Chmiel J, Detels R, Ervin C, Feldman J, Greenblatt R, Kingsley L. et al. Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. American Journal of Epidemiology 2003 158(7): 687-694.
20. Hernán MA, Cole SR, Margolick J, Cohen M, Robins JM. Structural accelerated failure time models for survival analysis in studies with time-varying treatments. Pharmacoepidemiology and Drug Safety 2005 14(7): 477-491.
21. Kaslow RA, Ostrow DG, Detels R, Phair JP, Polk BF, Rinaldo Jr CR. The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. American Journal of Epidemiology 1987 126(2): 310-318.
22. Barkan SE, Melnick SL, Preston-Martin S, Weber K, Kalish LA, Miotti P, Young M, Greenblatt R, Sacks H, Feldman J. The Women's Interagency HIV Study. WIHS Collaborative Study Group. Epidemiology 1998 9(2): 117-125.
23. CDC. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recommendations and Reports 1992 41(RR-17): 1-19.
24. Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, US Department of Health and Human Services and Henry J. Kaiser Family Foundation:Bethesda, MD, 2000. AIDSinfo [formerly HIV/AIDS Treatment Information Service], National Institutes of Health.
25. Cole SR, Hernán MA, Margolick JB, Cohen MH, Robins JM. Marginal structural models for estimating the effect of highly active antiretroviral therapy initiation on CD4 cell count. American Journal of Epidemiology 2005 162(5): 471-478.
26. Robins JM, Hernán MA.2008. Estimation of the causal effects of time-varying exposures, In Longitudinal Data Analysis, Fitzmaurice G, Davidian M, Verbeke G, Molenberghs G (eds), Chapman and Hall/CRC Press, New York; 553-599.
27. Hernán MA, Robins JM. Estimating causal effects from epidemiological data. Journal of Epidemiology and Community Health 2006 60(7): 578-586.
28. Westreich D, Cole SR. Invited commentary: positivity in practice. American Journal of Epidemiology 2010 171(6): 674-677 (discussion 678-681).
29. Cole SR, Frangakis CE. The consistency statement in causal inference: a definition or an assumption? Epidemiology 2009 20(1): 3-5.
30. Robins J, Hernán M.2008. Estimation of the causal effects of time-varying exposures, In Longitudinal Data Analysis, Fitzmaurice G, Davidian M, Verbeke G, Molenberghs G (eds), Chapman & Hall/CRC, Boca Raton, FL.
31. Toh S, Hernandez-Diaz S, Logan R, Robins JM, Hernan MA. Estimating absolute risks in the presence of nonadherence: an application to a follow-up study with baseline randomization. Epidemiology 2010 21(4): 528-539.
32. Cameron DW, Heath-Chiozzi M, Danner S, Cohen C, Kravcik S, Maurath C, Sun E, Henry D, Rode R, Potthoff A. et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet 1998 351(9102): 543-549.
33. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, Eron Jr JJ, Feinberg JE, Balfour Jr HH, Deyton LR. et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. New England Journal of Medicine 1997 337(11): 725-733.
34. Robins JM, Hernán MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000 11(5): 550-560.
35. Hernán MA, Lanoy E, Costagliola D, Robins JM. Comparison of dynamic treatment regimes via inverse probability weighting. Basic and Clinical Pharmacology and Toxicology 2006 98(3): 237-242.